Kathryn Horton, M.D. | Source | Internal Medicine Physician at Drugwatch.com

KM

Kathryn Horton, M.D.

Internal Medicine Physician at Drugwatch.com
On the record
Represented by:
Share profile 
Link:
Bio
Edit

Dr. Kathryn Horton is board-certified in Internal Medicine with a particular focus in Hospital Medicine. She is an active member of the Society of Hospital Medicine, and her current clinical interests include critical care medicine, obesity medicine and expanding patients’ access to providers via telemedicine. During her residency training, she spent a month in Manhattan working for the ABC News Medical Unit to research and deliver medical reports for multiple ABC media platforms, including Good Morning America and World News Tonight.

Employment
Sign up to view all
Story Ideas
Sign up to view all
  • Zepbound Surpasses Wegovy in Weight Loss Efficacy
    Dr. Horton explains Zepbound's dual hormonal targeting enhances insulin secretion and fat metabolism, outperforming Wegovy. "Patients may achieve greater weight loss with Zepbound," she notes. Individual health goals should guide treatment choice, considering Wegovy's cardiovascular benefits and adolescent use. A thorough patient evaluation is crucial before prescribing.
  • Wegovy: A New Hope in Obesity and Diabetes Management
    Dr. Horton explains that obesity drives diabetes through insulin resistance. "GLP-1 medications like Wegovy enhance insulin secretion and reduce appetite." Patients may lose 10-17% of body weight in a year. Common side effects include nausea and diarrhea, with serious risks like pancreatitis. Wegovy offers a promising approach when combined with diet and exercise.